About this medicine

The primary record here is Blackrock’s 10 mg tablet. Another checked UK SmPC also names Parnate; neither listing guarantees current branded stock.

This is a regular specialist antidepressant treatment, not an immediate calming medicine. A workable plan includes checking every new medicine and following the food restrictions after treatment ends as well as during treatment. The practical burden of those precautions is part of deciding whether it is suitable.

What is this medicine used for?

Blackrock’s licence covers adult major depressive episodes after other antidepressant types have failed. It is not indicated below 18.

Which warning signs need help?

Get emergency help for severe headache, neck stiffness, chest pain or palpitations. Avoid the leaflet’s tyramine/dopa-rich foods during treatment and for two weeks afterwards, including mature cheese, yeast/meat extracts, fermented or spoiled protein foods, broad-bean pods and alcoholic/non-alcoholic beer or wine. Follow the full diet sheet.

New self-harm thoughts, seizures, severe confusion or suspected overdose also need immediate assessment.

MHRA’s October 2026 communication announced the rollout of a prominent boxed warning in UK antidepressant patient leaflets about self-harm and suicidal behaviour, alongside a patient safety card. This UK patient-information measure is not the US FDA Boxed Warning designation. Read the leaflet supplied with your medicine, seek prompt professional help for new or worsening mood or behaviour changes, and do not stop treatment suddenly without advice.

A severe headache during treatment should not simply be treated with an over-the-counter cold or pain remedy while waiting: dangerously high blood pressure is one possibility. The leaflet also calls for prompt review of jaundice, unusual bruising, fever with sore throat, or new hallucinations or marked overactivity.

How do I take it safely?

Adult product reference: 10 mg morning and afternoon; an extra 10 mg at midday may be prescribed after a week. Doses above 30 mg daily need particular caution. Older people require slower increases and lower doses. Do not adjust treatment yourself.

The Blackrock leaflet advises taking the afternoon dose before 3 pm, reflecting the possibility of disturbed sleep. Swallow the tablets whole. The dose may be reduced once benefit is established; adding tablets because an early response is incomplete is unsafe. UK tablet instructions must not be replaced with the higher starting or maximum doses in an American Parnate label.

What side effects should I know about?

Insomnia, dizziness, dry mouth, nausea, tiredness and postural light-headedness are recognised.

Who needs extra care with this medicine?

Liver disease, phaeochromocytoma, hyperthyroidism, certain blood disorders and severe cardiovascular or cerebrovascular disease are contraindications.

Porphyria is another listed contraindication. Kidney impairment, epilepsy and a history of alcohol or drug dependence need particular assessment. Tell surgical and dental teams early: the UK leaflet describes a planned reduction and stopping at least two weeks before procedures when the anaesthetic requires it. Do not organise that withdrawal yourself.

Can it affect my other medicines?

The Blackrock leaflet excludes use within five weeks of fluoxetine, two weeks of other SSRIs or MAOIs, and three weeks of tricyclic/tetracyclic antidepressants. Pethidine, nefopam, dextromethorphan and decongestants can be dangerous. A specialist must determine the complete switch; these examples are not a protocol.

Examples involving cough remedies, decongestants and painkillers illustrate why non-prescription products matter. A pharmacist needs the actual ingredient, not only a brand name. Tranylcypromine can also interact with diabetes treatment and sedating antihistamines; a medicine sold without a prescription is not automatically safe alongside an MAOI.

What check-ups will I need?

Review blood pressure, standing dizziness, sleep, mood and medicine/food interactions. Inform the anaesthetist before planned procedures.

Monitor both high-pressure symptoms and dizziness on standing, which have different significance. Follow mood, sleep, daily functioning and any increase in the urge to take more medicine. Make sure the person can obtain and understand the current diet and interaction advice throughout treatment.

What about pregnancy, breastfeeding and age?

Pregnancy use is reserved for situations considered essential. Breastfeeding requires a decision about stopping nursing or treatment; older people need closer blood-pressure monitoring.

What if I miss a dose or want to stop?

Skip forgotten doses and never double up. Stopping is gradual under supervision; dietary restrictions continue for two weeks afterwards.

Abrupt stopping can cause nausea, vomiting, sweating and insomnia. The prescriber plans a reduction and the subsequent drug-free interval if another antidepressant is needed. Enzyme inhibition persists after the last tablet; neither feeling well nor a short blood half-life makes an early switch safe.

How does it work?

Tranylcypromine changes nerve-cell communication by reducing the breakdown of a group of chemical messengers called monoamines. It does this by inhibiting monoamine oxidase, an enzyme that helps process these chemicals. This is the proposed basis of its antidepressant action, although the full sequence leading to symptom improvement is not completely understood.

How Brain Cells Communicate

Nerve cells release chemical messengers called neurotransmitters, which attach to receptors and change the activity of other cells. Serotonin and norepinephrine are examples of monoamines, a family of these messengers. Monoamine oxidase, often shortened to MAO, helps break them down. This enzyme is one of the proteins the body uses to carry out chemical reactions and regulate the availability of messengers.

What is known: MAO participates in the breakdown of several chemical messengers.

What remains uncertain: Messenger availability is not a direct measurement of mood or depression.

How the process works

  1. Nerve-cell signal
  2. Receptor or transporter
  3. Network activity
MAO participates in the breakdown of several chemical messengers. Simplified illustration of the process; individual responses vary.
About this illustration

Nerve-cell signal; Receptor or transporter; Network activity. Messenger availability is not a direct measurement of mood or depression.

This is a simplified illustration. It does not show exactly how a medicine fits into a protein or predict a dose or response to treatment.

How the Medication Changes Signalling

Tranylcypromine is a monoamine oxidase inhibitor, or MAOI: it reduces the activity of this enzyme. Its inhibition is described as irreversible, meaning the affected enzyme stays inactive after the medicine has left the bloodstream. Slower messenger breakdown can strengthen some signals between nerve cells. The effect is broader than changing one serotonin receptor or one transport protein, and it does not establish that depression results from a simple chemical shortage.

What is known: Tranylcypromine produces lasting inhibition of MAO.

What remains uncertain: The amount of enzyme inhibition cannot predict an individual’s symptom improvement.

How the process works

  1. Tranylcypromine
  2. Molecular actions
  3. Clinical effects
Tranylcypromine produces lasting inhibition of MAO. Simplified illustration of the process; individual responses vary.
About this illustration

Tranylcypromine; Molecular actions; Clinical effects. The amount of enzyme inhibition cannot predict an individual’s symptom improvement.

This is a simplified illustration. It does not show exactly how a medicine fits into a protein or predict a dose or response to treatment.

A Closer Look at the Molecular Level

MAO in the intestine also breaks down tyramine, a substance present in some foods and drinks. When that process is reduced, more tyramine can reach the bloodstream and trigger a sudden, dangerous rise in blood pressure. MAO activity takes time to recover after tranylcypromine has left the body, so its interaction risks can persist after the last tablet. This explains why food restrictions and the washout period—the required gap before certain other medicines—depend on more than the drug’s blood level.

What is known: The effects on intestinal MAO help explain tyramine interactions.

What remains uncertain: Disappearance of the drug from the blood does not mean its interaction risks have ended.

How the process works

  1. Dose and metabolism
  2. Drug exposure
  3. Benefit and harm
The effects on intestinal MAO help explain tyramine interactions. Simplified illustration of the process; individual responses vary.
About this illustration

Dose and metabolism; Drug exposure; Benefit and harm. Disappearance of the drug from the blood does not mean its interaction risks have ended.

This is a simplified illustration. It does not show exactly how a medicine fits into a protein or predict a dose or response to treatment.

How does it affect my body?

Tyramine can accumulate and sharply increase blood pressure. Postural dizziness and disturbed sleep can occur separately.

How does my body process it?

The plasma half-life is about two hours, but enzyme inhibition persists much longer. Rapid blood clearance does not make another medicine safe immediately.

How do treatment options differ?

UK product doses differ from other MAOI regimens. SPS advises specialist support for switching and warns against many overlapping antidepressant combinations.

A closer look at the science

This non-hydrazine medicine irreversibly inhibits both MAO-A and MAO-B. It therefore differs structurally from phenelzine while sharing important interaction hazards.

Tranylcypromine is a non-hydrazine trans-phenylcyclopropylamine supplied as a sulfate salt.

Chemical formula: (C9H11N)2 · H2SO4

The product is racemic trans-tranylcypromine sulfate with two parent molecules per sulfate. The neutral-parent drawing, C9H11N, does not show the salt or specify a single-enantiomer product.

PubChem 2D depiction of neutral tranylcypromine; salt components omitted.
NCBI PubChem CID 5530. Lines are bonds; unlabeled corners are carbon and many hydrogen atoms are omitted. This neutral-parent drawing is connectivity, not a binding pose.

The drawing shows the neutral parent. The product salt formula is separately identified; neither determines release rate or dose.

How was this medicine developed?

The Blackrock record dates from February 2026; the separately checked Mercury/Parnate record dates from October 2005. These are product records, not discovery dates.

Sources and References

  1. Tranylcypromine 10 mg — UK SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  2. Parnate / Tranylcypromine 10 mg — UK SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  3. Tranylcypromine 10 mg — patient leaflet

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  4. NHS SPS: MAOI to other antidepressants, switching in adults

    Scope: NHS Specialist Pharmacy Service — professional medicines advice; individual and local implementation.

  5. Antidepressants: use and safety

    Scope: United Kingdom.

  6. Parnate prescribing information — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: 5.9 Persistence of MAO Inhibition after Discontinuation; 7.2 Tyramine-Containing Foods and Beverages; 12.1 Mechanism of Action; 12.2 Pharmacodynamics..

  7. What Is a Neurotransmitter? — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: How Neurotransmitters Work; Types of Neurotransmitters..

  8. Tranylcypromine: verified neutral parent, PubChem CID 5530

    Scope: International chemical identity; no prescribing jurisdiction.

  9. Schizophrenia
  10. NIMH: Understanding psychosis

Shared scientific background. US product pharmacology and international chemical records support molecular explanations only; UK product details and prescribing information are verified separately.

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top